At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 117 enrolled
Drug / intervention
LY3016859 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3016859 for the Treatment of Osteoarthritis
In Brief
A Phase 2 clinical trial evaluating LY3016859 and Placebo for Osteoarthritis. Completed, enrolled 117 participants across 33 sites in 2 countries.
Detailed Summary
This study is being done to test the safety and efficacy of LY3016859 for the treatment of osteoarthritis pain. This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartJul 2020
First PostedJul 2020
Primary CompletionApr 2021
Study CompletionAug 2021
TodayJul 2026
First PostedJul 2, 2020
Enrollment StartJul 1, 2020
Primary CompletionApr 22, 2021
Study CompletionAug 26, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6 years ago
Interventions
LY3016859drug
LY3016859 given IV.
Placebodrug
Placebo given IV.